Earnings call transcript: Alcidion Group sees 9% revenue growth in Q3 2026

Alcidion reported Q3 FY2026 contracted revenue of AUD 43.8 million, up 9% year over year, with positive operating cash flow of AUD 1.7 million and a cash balance of AUD 15.1 million with no debt. New sales TCV reached AUD 11.7 million, 90% from recurring product revenue, while management reaffirmed full-year guidance for revenue above AUD 50 million and EBITDA above AUD 5 million. The company also highlighted continued Miya Precision expansion, new AI-enabled capabilities, and a 10% share-price gain after the update.

Analysis

The core signal is not the quarter itself, but the inflection in mix: recurring software revenue is now being reinforced by module-led expansion rather than one-off implementations. That matters because the business is transitioning from a vendor-selection story to an installed-base monetization story, which typically improves visibility, gross margin durability, and multiple support even before headline growth reaccelerates. The 90% recurring mix in new wins also suggests management is successfully pushing buyers toward longer-duration commitments, which should compress churn risk and extend revenue duration into the 2030s.

The second-order winner is the platform architecture itself. Every new module added to an existing customer raises switching costs for both the EPR incumbent and adjacent point-solution competitors, especially in emergency and remote monitoring workflows where integration burden is high. That creates a “land, then outflank” dynamic: once the customer accepts the base workflow, new modules can be sold into budgeted optimization spend rather than competed as a full rip-and-replace event.

The key risk is timing, not demand. Near-term execution is lumpy because revenue recognition is increasingly dependent on a few late-cycle contracts and implementation milestones, so a slip in one larger negotiation could impact the market’s near-term confidence disproportionately. Longer term, the biggest threat is not another healthcare IT vendor, but procurement friction: if government buyers delay digital optimization budgets, the conversion from pipeline interest to signed revenue can stretch by 1-2 quarters and deflate the cash growth thesis.

Consensus likely underestimates how much the AI/automation layer can matter commercially before it becomes a standalone revenue driver. The real option value is workflow automation that reduces clinician friction and improves data quality; that tends to be the first feature set customers will pay to expand once the base platform is embedded. If this continues, the multiple should increasingly be driven by installed-base durability and cross-sell capacity rather than near-term earnings variance.

Key Decisions for Investors

• Long ALC on pullbacks over the next 2-4 weeks; use any post-rally consolidation to build a position for a 3-6 month catalyst window into contract signings and Q4 cash collection. Risk/reward is attractive if the market starts pricing recurring revenue durability rather than quarterly TCV noise.
• Pair trade: long ALC / short a broader healthcare IT peer basket that is more exposed to one-time implementation revenue. The thesis is that ALC’s mix shift toward recurring module expansion should deserve a higher durability multiple over the next 2 quarters.
• Buy near-dated call spreads on ALC if liquidity allows, targeting the next contract announcement window. This captures upside from a Sussex-style signing without paying full premium for a binary event.
• Avoid chasing the stock after strong contract headlines; instead, add only if management confirms sustained Q4 cash conversion or another module expansion at an existing site. The key risk is a timing slip that leaves the market with no fresh catalyst for 1-2 months.
• Monitor for a re-rating trigger if gross cash continues to rise while debt stays zero; if that persists through year-end, expect the market to begin underwriting a higher quality cash compounding story rather than a small-cap software recovery.